# Intezyne

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intezyne

- Industry: Pharmaceuticals
- Headquarters: Tampa, US
- Website: www.intezyne.com
- Total disclosed funding: $10M
- Latest round: Series A (Oct 6, 2017)
- Investors on record: 1

## About

Intezyne, Inc. specializes in developing innovative cancer therapies using proprietary technology for targeted drug delivery, aiming to improve treatment efficacy while reducing side effects.Intezyne, Inc. was founded in 2004 in Tampa, US, focusing on advanced cancer treatment solutions. The company has received a total of USD 10.00 mn in funding, led by Gaston Capital during its Series A round in October 2017. Intezyne has successfully completed three deals to date.Intezyne is focused on the development of advanced cancer therapies, particularly through its unique platform that leverages proprietary technology for targeted drug delivery. The company's core product offerings are designed to enhance the efficacy of existing cancer treatments while minimizing side effects. This is achieved through innovative formulations that allow for more precise targeting of cancer cells, which is critical in addressing various types of malignancies. Intezyne primarily serves oncology clinics, hospitals, and research institutions, which utilize these therapies in both clinical and experimental settings. The geographical markets for Intezyne’s products extend to North America, Europe, and select regions in Asia, where there is a growing demand for novel cancer treatments.Intezyne's revenue model is structured around partnerships with healthcare providers and institutions that aim to integrate their therapies into clinical practice. Transactions typically occur through B2B agreements, where the firm collaborates with hospitals and oncology centers to supply its specialized cancer therapies. These partnerships are often established through licensing agreements and collaborations for clinical trials, allowing for a streamlined introduction of their products into the market. The company focuses on securing contracts that ensure a steady flow of revenue as their therapies progress through various stages of clinical development. Intezyne’s flagship offerings are positioned to command competitive pricing within the oncology drug market, reflecting their innovative approach to cancer treatment, although specific pricing details are not disclosed.Intezyne plans to leverage the USD 10.00 mn raised during its Series A funding round to support the development of new products aimed at enhancing cancer treatment efficacy. The company is also strategizing to expand its market presence in Europe and select regions in Asia by the end of 2025, capitalizing on the growing demand for targeted cancer therapies. Additionally, the recent funding will facilitate the development of clinical trial partnerships necessary for bringing their innovative products to market.

## Funding rounds

- Series A, Oct 6, 2017, $10M — Gaston Capital

## Investors

- Gaston Capital (https://capitalatlas.ai/funds/gaston-capital) — Series A